Seattle's youngest public biotech seeks a buyer after filing for bankruptcy protection

PhaseRx went public in May in an $18.5 million initial public offering, which it has used to develop its pipeline of drug treatments for a rare liver disease that affects children.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news